RxDoctor Payments Data

Barbara Martinez Escobar, MD

Family Medicine · Pembroke Pines, FLNPI 1649435041

Payments from drug & device makers

$4,167in general payments, 2019–2025

Across 236 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$613
  • Kowa Pharmaceuticals America, Inc.$465
  • Boehringer Ingelheim$446
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$338
  • AbbVie$305
  • GSK$295
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,14299%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,167 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$32,306
Medicare patients
88
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol43$30,593
JardianceEmpagliflozin27$26,643
OzempicSemaglutide23$25,799
EliquisApixaban37$25,694
TradjentaLinagliptin26$24,022
MounjaroTirzepatide18$19,522
LinzessLinaclotide19$17,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,620
XareltoRivaroxaban17$11,103
Tresiba Flextouch U-100Insulin Degludec13$6,252
SynthroidLevothyroxine Sodium32$3,216
Rosuvastatin Calcium188$3,186
Atorvastatin Calcium243$2,407
Nifedipine ErNifedipine40$2,309
Levothyroxine Sodium146$1,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$446$50,66453 claims
AstraZenecaFarxiga$278$30,59343 claims
Novo NordiskOzempic$17$25,79923 claims
PfizerEliquis$271$25,69437 claims
AbbVieLinzess, Synthroid$305$20,39251 claims
Lilly USA, LLCMounjaro$199$19,52218 claims
GSKTrelegy Ellipta$295$12,62020 claims
Johnson & JohnsonXarelto$110$11,10317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →